Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Core Viewpoint - Silo Pharma, Inc. has received a Notice of Allowance for a patent that will enhance its intellectual property protection for its lead asset, SPC-15, which targets PTSD treatment [1][2] Group 1: Patent and Intellectual Property - The U.S. Patent and Trademark Office will issue a patent for biomarkers related to prophylactic treatments against stress-induced affective disorders, expected to be U.S. Patent No. 12,329,726 on June 17, 2025 [1][2] - This patent strengthens Silo's IP protection for SPC-15, an intranasal treatment for PTSD [2][3] Group 2: Product Development - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders, including PTSD and anxiety [4] - The product is eligible for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating its approval process [4] - Silo Pharma is preparing to initiate Phase 1 clinical trials for SPC-15 [3] Group 3: Company Overview - Silo Pharma focuses on developing treatments for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5] - The company's portfolio includes other innovative programs like SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [5]